Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)

Brose, MS; Smit, JWA; Lin, CC; Tori, M; Bowles, DW; Worden, F; Shen, DHY; Huang, SM; Tsai, HJ; Alevizaki, M; Peeters, RP; Takahashi, S; Rumyantsev, P; Guan, RJ; Babajanyan, S; Ozgurdal, K; Sugitani, I; Pitoia, F; Lamartina, L

Brose, MS (通讯作者)，Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19144 USA.

THYROID, 2022; 32 (9): 1059

Abstract

Background: Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients with radioactive iodine-refractory (RAI-R) differentiated......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索